Your browser doesn't support javascript.
loading
Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women.
Evans, D Gareth; Howell, Sacha J; Gandhi, Ashu; van Veen, Elke M; Woodward, Emma R; Harvey, James; Barr, Lester; Wallace, Andrew; Lalloo, Fiona; Wilson, Mary; Hurley, Emma; Lim, Yit; Maxwell, Anthony J; Harkness, Elaine F; Howell, Anthony.
Afiliação
  • Evans DG; Clinical Genetics Service, Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK. gareth.evans@mft.nhs.uk.
  • Howell SJ; NW Genomic Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK. gareth.evans@mft.nhs.uk.
  • Gandhi A; Division of Evolution and Genomic Sciences, Faculty of Biology, Manchester Academic Health Science Centre, School of Biological Sciences, Medicine and Health, University of Manchester, Manchester, UK. gareth.evans@mft.nhs.uk.
  • van Veen EM; Nightingale/Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK. gareth.evans@mft.nhs.uk.
  • Woodward ER; Manchester Breast Centre, Manchester Cancer Research Centre, The Christie Hospital, Manchester, UK. gareth.evans@mft.nhs.uk.
  • Harvey J; Department of Genetic Medicine, Manchester Academic Health Sciences Centre (MAHSC), St Mary's Hospital, University of Manchester, Manchester, M13 9WL, UK. gareth.evans@mft.nhs.uk.
  • Barr L; Nightingale/Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK.
  • Wallace A; Manchester Breast Centre, Manchester Cancer Research Centre, The Christie Hospital, Manchester, UK.
  • Lalloo F; Division of Cancer Sciences, Faculty of Biology, Manchester Academic Health Science Centre, Medicine and Health, University of Manchester, Manchester, UK.
  • Wilson M; Nightingale/Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK.
  • Hurley E; Manchester Breast Centre, Manchester Cancer Research Centre, The Christie Hospital, Manchester, UK.
  • Lim Y; Division of Cancer Sciences, Faculty of Biology, Manchester Academic Health Science Centre, Medicine and Health, University of Manchester, Manchester, UK.
  • Maxwell AJ; NW Genomic Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK.
  • Harkness EF; Division of Evolution and Genomic Sciences, Faculty of Biology, Manchester Academic Health Science Centre, School of Biological Sciences, Medicine and Health, University of Manchester, Manchester, UK.
  • Howell A; Clinical Genetics Service, Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK.
Breast Cancer Res Treat ; 189(3): 677-687, 2021 Oct.
Article em En | MEDLINE | ID: mdl-34312777
ABSTRACT

PURPOSE:

Women at increased familial breast cancer risk have been offered screening starting at an earlier age and increased frequency than national Screening Programmes for over 30 years. There are limited data on longer-term largescale implementation of this approach on cancer diagnosis.

METHODS:

Women at our institution at ≥ 17% lifetime breast cancer risk have been offered enhanced screening with annual mammography starting at age 35 or 5-years younger than youngest affected relative, with upper age limit 50 for moderate and 60 for high-risk. Breast cancer pathology, stage and receptor status were assessed as well as survival from cancer diagnosis by Kaplan-Meier analysis.

RESULTS:

Overall 14,311 women were seen and assessed for breast cancer risk, with 649 breast cancers occurring in 129,119 years follow up (post-prevalent annual incidence = 4.55/1000). Of 323/394 invasive breast cancers occurring whilst on enhanced screening, most were lymph-node negative (72.9%), T1 (≤ 20 mm, 73.2%) and stage-1 (61.4%), 126/394 stage2-4 (32%). 10-year breast cancer specific survival was 91.3% (95% CI 87.4-94.0) better than the 75.9% (95% CI 74.9-77.0) published for England in 2013-2017. As expected, survival was significantly better for women with screen detected cancers (p < 0.001). Ten-year survival was particularly good for those diagnosed ≤ 40 at 93.8% (n = 75; 95% CI 84.2-97.6). Women with lobular breast cancers had worse 10-year survival at 85.9% (95% CI 66.7-94.5). Breast cancer specific survival was good for 119 BRCA1/2 carriers with 20-year survival in BRCA191.2% (95% CI 77.8-96.6) and 83.8% (62.6-93.5) for BRCA2.

CONCLUSIONS:

Targeted breast screening in women aged 30-60 years at increased familial risk is associated with good long-term survival that is substantially better than expected from population data.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido